Qianjin Pharmaceuticals (600479.SH) held a subsidiary that has obtained a drug registration certificate.

Intelligence Financial APP News, Qianjin Pharmaceutical (600479.SH) announced that recently, its subsidiary Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. ("Qianjin Xiangjiang Pharmaceutical") received the approved Adenosine Cobamamide Capsules (0.5mg) "Drug Registration Certificate" (Certificate No.: 2025S02155) issued by the National Medical Products Administration. The company's subsidiary Hunan Qianjin XieLi Pharmaceutical Co., Ltd. ("Qianjin XieLi Pharmaceutical") received the approved Sacubitril Valsartan Tablets (100mg) "Drug Registration Certificate" (Certificate No.: 2025S02192) issued by the National Medical Products Administration.